Equities

Biotest AG

  • Add to watchlist
  • Add to portfolio
  • Add an alert

Biotest AG

Actions
  • Price (EUR)37.00
  • Today's Change0.20 / 0.54%
  • Shares traded1.00
  • 1 Year change-7.96%
  • Beta-0.0804
Data delayed at least 15 minutes, as of Feb 16 2026 07:44 GMT.
More ▼
Notice
Important Notice
Please note that effective 5th February, 2026 the Financial Times will no longer publish or present securities from the Nairobi Stock Exchange.

Profile data is unavailable for this security.

About the company

Biotest AG is a Germany-based provider of plasma proteins and biological drugs. The Company, with a chain that extends from pre-clinical and clinical development to worldwide marketing and distribution, mainly specializes in the areas of clinical immunology, hematology, and intensive care medicine. It develops, manufactures, and markets immunoglobulin, coagulation factors, and albumins based on human blood plasma. These are used for diseases of the immune and hematopoietic systems. In addition, the Company develops monoclonal antibodies in the indications of cancer of plasma cells and systemic lupus erythematosus, which are produced by recombinant technologies.

  • Revenue in EUR (TTM)635.20m
  • Net income in EUR-24.50m
  • Incorporated2006
  • Employees2.50k
  • Location
    Biotest AGLandsteinerstr. 5DREIEICH 63303GermanyDEU
  • Phone+49 61038010
  • Fax+49 6 103801150
  • Websitehttps://www.biotest.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Chengdu Olymvax Biopharmaceuticals Inc86.48m7.83m1.34bn470.00170.9411.47--15.520.15870.15871.752.360.38830.6541.191,508,792.003.453.255.004.8192.6693.628.888.111.428.300.29067.3918.6926.8818.24--48.00--
Shanghai Yizhong Pharmaceutical Co Ltd30.13m2.80m1.34bn65.00471.027.54--44.600.11320.11321.227.070.1630.95562.263,800,801.001.515.441.585.6481.3992.999.3036.907.84--0.0032.30-51.83---95.68--10.96--
Jubilant Pharmova Ltd736.77m40.26m1.35bn978.0033.53--17.041.8327.2327.23498.28--------80,965,230.00--3.37--4.0267.7164.545.425.64--4.06--21.607.933.90988.726.7314.210.00
Biotest AG635.20m-24.50m1.36bn2.50k--2.86--2.14-0.6505-0.650516.3712.880.44371.012.88254,589.20-1.720.4411-2.130.513723.1928.69-3.870.92251.660.2680.567513.416.0811.62-79.21---3.39--
Veradermics Inc0.00-45.34m1.37bn19.00---------1.53-1.530.000.3731------0.00--------------------0.00-------60.63------
Cansino Biologics Inc118.52m-17.32m1.37bn1.11k--2.99--11.55-0.5455-0.54553.9221.370.12710.58611.38879,482.50-1.86-4.08-2.29-5.3878.8045.31-14.62-27.513.29--0.2242--137.01226.4374.45--31.38--
Zhejiang CONBA Pharmaceutical Co., Ltd.802.21m83.91m1.37bn8.26k16.621.58--1.710.26650.26652.542.800.66172.574.70796,529.007.138.519.6512.7451.8858.6410.7714.121.38--0.053241.54-3.23-0.75945.21--1.57--
Natco Pharma Ltd424.30m144.89m1.37bn4.20k9.48--8.203.2486.9486.94254.62--------10,860,210.00--15.82--18.1482.7975.2233.8730.39--44.51--12.0910.7718.2635.8132.557.37-2.33
Immunocore Holdings PLC - ADR319.83m-24.62m1.37bn493.00------4.30-0.5866-0.58667.49--0.34710.53365.44769,959.40-2.67-17.90-3.34-23.2699.29---7.70-53.745.97--0.4975--24.3756.777.60---1.06--
Guangzhou Innogen Pharmaceutl Grp Co Ltd-10.78bn-10.78bn1.38bn105.00--15.00----------1.84------------------------3.39--0.0769------76.18------
Vimian Group AB424.15m31.13m1.38bn1.20k44.401.9819.693.260.62650.62658.5414.020.3831.677.56--2.921.423.271.6268.9069.187.623.961.227.960.25190.0013.4242.9474.59-9.3621.97--
Pharma Mar SA179.28m34.01m1.38bn500.0039.736.8332.857.711.931.9310.2111.240.53140.19465.34358,552.0010.0818.3713.7025.0394.5394.0218.9729.812.14--0.2031--10.5615.302,197.71--31.72--
Chengdu Easton Biopharmaceuticals Co Ltd162.08m29.44m1.39bn1.52k46.913.97--8.551.371.377.5516.230.38091.835.89873,161.506.928.098.449.8271.9081.7218.1620.103.12--0.044430.3720.827.345.1517.014.24--
Data as of Feb 16 2026. Currency figures normalised to Biotest AG's reporting currency: Euro EUR

Institutional shareholders

0.08%Per cent of shares held by top holders
HolderShares% Held
Arvernus Capital AGas of 30 Sep 202513.23k0.07%
BANTLEON Invest GmbHas of 30 Nov 20232.00k0.01%
Ersel Asset Management SGR SpAas of 30 Jun 20250.000.00%
Data from 29 Aug 2025 - 30 Dec 2025Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.